China Biotech Services Holdings Limited (8037.HK)

HKD 0.49

(6.52%)

Market Cap (In HKD)

478.1 Million

Revenue (In HKD)

211.98 Million

Net Income (In HKD)

-95.44 Million

Avg. Volume

217.03 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.25-0.8
PE
-
EPS
-
Beta Value
-0.742
ISIN
BMG2152F1014
CUSIP
G2152F101
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Xiaolin Liu
Employee Count
-
Website
https://www.cbshhk.com
Ipo Date
2004-06-17
Details
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through five segments: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, Insurance brokerage, and Others segments. It also engages in the research, development, manufacture, sale, and distribution of health related and pharmaceutical products; trading of securities; money lending business; provision of tumor immune cell therapy, immune cell storage, and health management services; and provision of coordination of healthcare providers services. In addition, the company markets and sells health supplements, slimming pills, Chinese medicines, and beauty products; trades in pharmaceutical intermediates; and offers insurance brokerage services. Further, it provides property investment and logistic services. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.